TY - JOUR
AU - Jha, Niraj Kumar
AU - Jeyaraman, Madhan
AU - Rachamalla, Mahesh
AU - Ojha, Shreesh
AU - Dua, Kamal
AU - Chellappan, Dinesh Kumar
AU - Muthu, Sathish
AU - Sharma, Ankur
AU - Jha, Saurabh Kumar
AU - Jain, Rashmi
AU - Jeyaraman, Naveen
AU - GS, Prajwal
AU - Satyam, Rohit
AU - Khan, Fahad
AU - Pandey, Pratibha
AU - Verma, Nitin
AU - Singh, Sandeep Kumar
AU - Roychoudhury, Shubhadeep
AU - Dolpuria, Sunny
AU - Ruokolainen, Janne
AU - Kesari, Kavindra Kumar
PY - 2021
DA - March
TI - Current understanding of novel coronavirus: molecular pathogenesis, diagnosis, and treatment approaches
JO - Immuno
EP - 66
VL - 1
IS - 1
DO - https://doi.org/10.3390/immuno1010004
AB - An outbreak of "Pneumonia of Unknown Etiology" occurred in Wuhan, China, in late December 2019. Later, the agent factor was identified and coined as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the disease was named coronavirus disease 2019 (COVID-19). In a shorter period, this newly emergent infection brought the world to a standstill. On 11 March 2020, the WHO declared COVID-19 as a pandemic. Researchers across the globe have joined their hands to investigate SARS-CoV-2 in terms of pathogenicity, transmissibility, and deduce therapeutics to subjugate this infection. The researchers and scholars practicing different arts of medicine are on an extensive quest to come up with safer ways to curb the pathological implications of this viral infection. A huge number of clinical trials are underway from the branch of allopathy and naturopathy. Besides, a paradigm shift on cellular therapy and nano-medicine protocols has to be optimized for better clinical and functional outcomes of COVID-19-affected individuals. This article unveils a comprehensive review of the pathogenesis mode of spread, and various treatment modalities to combat COVID-19 disease.
PB - MDPI
UR - https://strathprints.strath.ac.uk/83119/
KW - Coronavirus (COVID-19)
ER